- Home
- PSHG vs CARA Comparison
PSHG vs CARA Comparison
Compare PSHG & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- CARA
- Stock Information
- Founded
- PSHG 2010
- CARA 2004
- Country
- PSHG Greece
- CARA United States
- Employees
- PSHG N/A
- CARA N/A
- Industry
- PSHG Marine Transportation
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- CARA Health Care
- Exchange
- PSHG Nasdaq
- CARA Nasdaq
- Market Cap
- PSHG 20.3M
- CARA 23.1M
- IPO Year
- PSHG N/A
- CARA 2014
- Fundamental
- Price
- PSHG $1.64
- CARA $4.97
- Analyst Decision
- PSHG Strong Buy
- CARA Hold
- Analyst Count
- PSHG 1
- CARA 3
- Target Price
- PSHG $6.50
- CARA $12.00
- AVG Volume (30 Days)
- PSHG 79.5K
- CARA 25.0K
- Earning Date
- PSHG 02-20-2025
- CARA 03-03-2025
- Dividend Yield
- PSHG N/A
- CARA N/A
- EPS Growth
- PSHG N/A
- CARA N/A
- EPS
- PSHG 1.51
- CARA N/A
- Revenue
- PSHG $89,608,000.00
- CARA $8,686,000.00
- Revenue This Year
- PSHG N/A
- CARA N/A
- Revenue Next Year
- PSHG N/A
- CARA N/A
- P/E Ratio
- PSHG $1.11
- CARA N/A
- Revenue Growth
- PSHG N/A
- CARA N/A
- 52 Week Low
- PSHG $1.51
- CARA $2.71
- 52 Week High
- PSHG $2.58
- CARA $13.80
- Technical
- Relative Strength Index (RSI)
- PSHG 46.17
- CARA 49.66
- Support Level
- PSHG $1.53
- CARA $4.94
- Resistance Level
- PSHG $1.68
- CARA $5.73
- Average True Range (ATR)
- PSHG 0.07
- CARA 0.30
- MACD
- PSHG 0.01
- CARA -0.04
- Stochastic Oscillator
- PSHG 65.79
- CARA 30.28
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.